Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1645 1653
This examiner grants 69% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18162508 | ANTIGEN BINDING RECEPTORS | Non-Final OA | Hoffmann-La Roche Inc. |
| 17762694 | KNOTTIN-IMMUNOSTIMULANT CONJUGATES AND RELATED COMPOSITIONS AND METHODS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17608709 | ENHANCEMENT OF POLYPEPTIDES AND CHIMERIC ANTIGEN RECEPTORS VIA HINGE DOMAINS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17635444 | MATERIALS AND METHODS FOR ACTIVATING ANTIGEN-SPECIFIC T CELL RESPONSES | Final Rejection | NORTHWESTERN UNIVERSITY |
| 17998521 | DOSING AND ADMINISTRATION OF ACTIVATABLE ANTI-CTLA-4 ANTIBODY | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 17639794 | PROTEINS COMPRISING T-CELL RECEPTOR CONSTANT DOMAINS | Final Rejection | The University of North Carolina at Chapel Hill |
| 17597793 | COMPOSITIONS AND METHODS COMPRISING PROTEASE-ACTIVATED THERAPEUTIC AGENTS | Non-Final OA | The University of Chicago |
| 18324668 | ANTI-BCMA ANTIBODIES | Non-Final OA | SANOFI |
| 17786186 | MULTI-SPECIFIC T CELL RECEPTORS | Non-Final OA | OREGON HEALTH & SCIENCE UNIVERSITY |
| 17604324 | ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR COMBINATION THERAPY | Final Rejection | Millennium Pharmaceuticals, Inc. |
| 18034221 | ENZYME-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | Non-Final OA | Trustees of Tufts College |
| 18034225 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | Non-Final OA | Trustees of Tufts College |
| 17783171 | ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF | Final Rejection | The U.S.A., as Represented by the Secretary, Department of Health and Human Services |
| 17793271 | METHODS OF STIMULATING AN ANTI-TUMOR RESPONSE USING A SELECTIVE GLUCOCORTICOID RECEPTOR MODULATOR | Final Rejection | Corcept Therapeutics Incorporated |
| 18025202 | BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | Non-Final OA | GENMAB A/S |
| 17631701 | ANTIGEN RECEPTOR | Final Rejection | MIE UNIVERSITY |
| 18039060 | TCR CAPABLE OF RECOGNIZING HPV ANTIGEN | Non-Final OA | XLIFESC, LTD. |
| 18038627 | BISPECIFIC ANTIBODY AND USE THEREOF | Non-Final OA | HUABO BIOPHARM (SHANGHAI) CO., LTD. |
| 17602061 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | Non-Final OA | Universidade de Santiago de Compostela |
| 18017849 | COMBINATORIAL ANTIGEN RECOGNITION IN CANCER T CELL THERAPIES | Non-Final OA | THE SIMONS FOUNDATION, INC. |
| 18015544 | ENGINEERED IMMUNE CELL FOR ALLOTRANSPLANTATION | Non-Final OA | NANJING BIOHENG BIOTECH CO., LTD |
| 17802242 | NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | Final Rejection | NANJING BIOHENG BIOTECH CO., LTD |
| 17907300 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | Non-Final OA | Brian GRANDA |
| 17908222 | CORONAVIRUS VACCINES COMPRISING A TLR9 AGONIST | Non-Final OA | MEDIGEN VACCINE BIOLOGICS CORPORATION |
| 17507456 | CONDITIONING METHODS FOR GENE THERAPY | Final Rejection | Magenta Therapeutics, Inc. |
| 17723084 | Bispecific Antibodies for Activation of Immune Cells | Non-Final OA | JN BIOSCIENCES LLC |
| 17609777 | GPCR HETEROMER INHIBITORS AND USES THEREOF | Non-Final OA | GPCR THERAPEUTICS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy